Germany | Bayern

Zurück zur Suche

Internationale Partnersuche

Forschung & Entwicklung Anfrage

Hungarian SME is looking for Turkish manufacturing company of small molecules and university research group for joint Turkish-Hungarian bilateral grant application.

Country of Origin: Hungary
Reference Number: RDHU20201125001
Publication Date: 25 November 2020

Summary

A Hungarian pharma/biotechnology R&D company is developing novel matrix metalloproteinase inhibitor small molecules for treatment of ischemic diseases, e.g. ischemic cardiac disease, such as e.g. acute myocardial infarction. The company seeks partners to further develop the molecules in a joint Hungarian-Turkish grant application. Turkish partners needed: small molecule manufacturing company and university research group with experience in lead optimization with in silico platform.

Description

Acute myocardial infarction is an unmet medical need with currently no medication on the market. Only symptomatic drug treatment is available for patients with acute myocardial infarction. Ischemic heart disease including e.g. acute myocardial infarction and heart failure is still the leading cause of death worldwide with over 8,5 million deaths/year. In the 28 countries of the European Union ischemic heart disease is the 2nd cause of death with over 3,3 million deaths/year.

The coordinator of the planned project is a Hungarian pharma/biotechnology R&D company developing novel in-house R&D projects and providing innovative preclinical and clinical R&D services since 2003. The company is a worldwide R&D service provider with opinion leader scientific management. As development of the Matrix metalloproteinase inhibitor (MMPI) molecules has reached in vivo preclinical proof of concept stage, the coordinator company is now preparing for further fundraising and co-development under a joint Hungarian-Turkish grant application.

The project will be carried out by a small consortium of 4 partners. The Hungarian university will perform in vivo tests of MMPI molecules in cooperation with the Hungarian company.

Partners sought from Turkey:
- manufacturing company with proven track record of small molecule synthesis, manufacturing of high-quality small molecules, preferably Current Good Manufacturing Practice (cGMP) certified. Tasks: manufacturing of the MMPI molecules
- academic research group with outstanding scientific excellence in in silico lead optimization, target analysis, and in silico docking studies

- Deadline for EOIs: 11 January 2021.

Advantages and Innovations

Matrix metalloproteinases (MMPs, Zn-dependent endopeptidases, 28 known izoenzymes) are promising drug targets for myocardial infarction and post-infarction heart failure. 

The Hungarian company has developed several novel selective MMPIs lead molecules that open new therapeutic option to treat the abovementioned pathologies.

The MMPI development project utilizes a novel chemistry approach, i.e. reverse development strategy to MMPIs as well as a soft warhead concept to increase the selectivity. By this approach, the Hungarian company developed several novel cardioprotective MMPI lead molecules.

Current development status: in vivo preclinical proof-of-concept study completed, currently in lead optimization stage.

Stage Of Development

Prototype available for demonstration

Requested partner

Partner 1
- Type of partner sought: Industry
- Specific area of activity of the partner: - manufacturing company with proven track record of small molecule synthesis, manufacturing of high-quality small molecules, preferably cGMP certified.
- Task to be performed: During the project the partner’s tasks will include scale-up and manufacturing of the MMPI small molecules (up to 10g quantities).
After the project, the partner could be involved in the commercialization of the project results as well.

Partner 2
- Type of partner sought: Academic Research Group
- Specific area of activity of the partner: - academic research group with outstanding scientific excellence in bioinformatics, target analysis, and in silico docking studies.
- Task to be performed: perform chemo- and bioinformatics, in silico off-target assessment, and in silico docking studies on MMPI small molecules.

Dissemination Countries

Turkey

Cooperation offer ist closed for requests